2563 — Beijing Biostar Pharmaceuticals Share Price
Last trade - 00:00- HK$1.48bn
- HK$929.82m
- CNY33.36m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.97 | ||
| Price to Tang. Book | 2.01 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 22.84 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -15.52% | ||
| Return on Equity | -15% | ||
| Operating Margin | -190.71% | ||
Financial Summary
| Year End 31st Dec | Unit | 2021 | 2022 | 2023 | 2024 | 2025 | 2026E | 2027E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | CNYm | n/a | 32.82 | 66.64 | 71.87 | 33.36 | 473.52 | 1,006.59 | 0.55% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Beijing Biostar Pharmaceuticals Co Ltd is a Chinea-based company principally engaged in the research, development, production and sales of innovative drugs. The Company's products and pipeline mainly include Utidelone Injection, Utidelone Capsule, Utidelone Nanoformulation, Utidelone Antibody Drug Conjugate (ADC), BG22, BG18 and BG44. The Company's products are principally used for the treatment of relapsed or metastatic breast cancer, neoadjuvant treatment of human epidermal growth factor receptor 2 (HER2)-breast cancer neoadjuvant, advanced non-small cell lung cancer (NSCLC), solid tumors, breast cancer brain metastasis, lung cancer brain metastasis and other brain tumor indications. The Company mainly conducts its businesses in the domestic market.
Directors
- Last Annual
- December 31st, 2025
- Last Interim
- June 30th, 2026
- Incorporated
- July 11th, 2002
- Public Since
- October 31st, 2024
- No. of Employees
- 127
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- Stock Exchange of Hong Kong Limited
- Shares in Issue
- 389,588,000
- Address
- 1202, Tower B, BEIJING
- Web
- https://www.biostar-pharm.com/
- Phone
- Auditors
- WUYIGE Cerfified Public Accountants LLP
Latest News for 2563
Upcoming Events for 2563
Full Year 2026 Beijing Biostar Pharmaceuticals Co Ltd Earnings Release
Similar to 2563
160 Health International
Stock Exchange of Hong Kong Limited
3D Medicines
Stock Exchange of Hong Kong Limited
3SBio
Stock Exchange of Hong Kong Limited
Ab&B Bio Tech JS
Stock Exchange of Hong Kong Limited
AIM Vaccine
Stock Exchange of Hong Kong Limited
FAQ
As of Today at 01:38 UTC, shares in Beijing Biostar Pharmaceuticals are trading at HK$3.80. This share price information is delayed by 15 minutes.
Shares in Beijing Biostar Pharmaceuticals last closed at HK$3.80 and the price had moved by -28.3% over the past 365 days. In terms of relative price strength the Beijing Biostar Pharmaceuticals share price has underperformed the FTSE Developed Asia Pacific Index by -46.76% over the past year.
The overall consensus recommendation for Beijing Biostar Pharmaceuticals is Strong Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreBeijing Biostar Pharmaceuticals does not currently pay a dividend.
Beijing Biostar Pharmaceuticals does not currently pay a dividend.
Beijing Biostar Pharmaceuticals does not currently pay a dividend.
To buy shares in Beijing Biostar Pharmaceuticals you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of HK$3.80, shares in Beijing Biostar Pharmaceuticals had a market capitalisation of HK$1.48bn.
Here are the trading details for Beijing Biostar Pharmaceuticals:
- Country of listing: Hong Kong
- Exchange: HKG
- Ticker Symbol: 2563
Based on an overall assessment of its quality, value and momentum Beijing Biostar Pharmaceuticals is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Beijing Biostar Pharmaceuticals is HK$35.93. That is 845.43% above the last closing price of HK$3.80.
Analysts covering Beijing Biostar Pharmaceuticals currently have a consensus Earnings Per Share (EPS) forecast of CNY0.14 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Beijing Biostar Pharmaceuticals. Over the past six months, its share price has underperformed the FTSE Developed Asia Pacific Index by -2.77%.
As of the last closing price of HK$3.80, shares in Beijing Biostar Pharmaceuticals were trading -0.09% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Beijing Biostar Pharmaceuticals PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at HK$3.80.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
We do not have data on Beijing Biostar Pharmaceuticals' directors